COLEC11

Across TCGA pan-cancer cohorts, COLEC11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COLEC11 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher COLEC11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated COLEC11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where COLEC11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.895	0.645	.005	23	view →
LUAD	OS	Median	All	0.868	0.999	.013	23	view →
CCRCC	DFS	Median	All	0.859	0.633	.008	21	view →
LSCC	DFS	Median	All	0.524	0.882	.008	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COLEC11–PDAC (DFS)

Open the PDAC breakdown →